Ken Griffin’s Repros Therapeutics Inc. RPRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2016
Q1 | – | Sell |
-5,800
| Closed | -$7K | – | 9366 |
|
|
2015
Q4 | $7K | Sell |
5,800
-900
| -13% | -$2.89K | ﹤0.01% | 8401 |
|
|
2015
Q3 | $50K | Buy |
6,700
+5,300
| +379% | +$40.5K | ﹤0.01% | 7593 |
|
|
2015
Q2 | $10K | Sell |
1,400
-5,400
| -79% | -$42.1K | ﹤0.01% | 8426 |
|
|
2015
Q1 | $58K | Sell |
6,800
-25,400
| -79% | -$227K | ﹤0.01% | 7293 |
|
|
2014
Q4 | $321K | Buy |
32,200
+3,300
| +11% | +$28.1K | ﹤0.01% | 5335 |
|
|
2014
Q3 | $286K | Buy |
28,900
+2,900
| +11% | +$42.9K | ﹤0.01% | 5322 |
|
|
2014
Q2 | $450K | Sell |
26,000
-6,600
| -20% | -$108K | ﹤0.01% | 4541 |
|
|
2014
Q1 | $578K | Sell |
32,600
-9,700
| -23% | -$188K | ﹤0.01% | 4146 |
|
|
2013
Q4 | $774K | Sell |
42,300
-23,100
| -35% | -$436K | ﹤0.01% | 3498 |
|
|
2013
Q3 | $1.75M | Sell |
65,400
-12,200
| -16% | -$261K | ﹤0.01% | 2542 |
|
|
2013
Q2 | $1.43M | Buy |
+77,600
| New | +$1.37M | ﹤0.01% | 2812 |
|
Ken Griffin's RPRX Position: Q1 2018 in Review
Ken Griffin sold out of Repros Therapeutics Inc. (RPRX) in Q1 2018, closing a stake of 15,518 shares — an estimated $10K sold.
Ken Griffin first reported a position in RPRX in Q2 2013 and held it in 11 quarters. The position peaked at $35.8M in Q3 2013. 1 fund tracked by Wall St. Rank holds RPRX as of Q1 2018.
- Ken Griffin reported no remaining Repros Therapeutics Inc. position as of Q1 2018 after selling out during the quarter.
- Ken Griffin sold 15,518 Repros Therapeutics Inc. shares in Q1 2018, an estimated $10K.
- Ken Griffin first reported a position in Repros Therapeutics Inc. in Q2 2013 and held it in 11 quarters.
- Ken Griffin's Repros Therapeutics Inc. position peaked at $35.8M in Q3 2013.
- 1 fund tracked by Wall St. Rank held Repros Therapeutics Inc. as of Q1 2018.
Based on Citadel Advisors's 13F filing for Q1 2018, filed 11 May 2018.